HLSE:ORNBVPharmaceuticals
A Look At Orion Oyj’s Valuation After ODM-212 Phase 1 Results At The 2026 ASCO Meeting
Orion Oyj (HLSE:ORNBV) has attracted fresh attention after presenting first Phase 1 data for its oral pan TEAD inhibitor ODM-212 at the 2026 ASCO meeting, highlighting early safety and activity signals in difficult solid tumors.
See our latest analysis for Orion Oyj.
The recent ODM-212 data appear to be feeding into growing interest in Orion, with the share price at €69.85 and a year to date share price return of 10.35%, while the 1 year total shareholder return of 14.38% sits within a much...